Advanced Solutions
for Advanced Pathology
CD38 (SP149)
Rabbit Monoclonal Antibody
Cat. No. Description
Volume
45276 IMPATH CD38 RTU R (SP149)
50 Tests
44237 CD38 RTU R (SP149)
7 ml Ready To Use
44496 CD38 0,1 R (SP149)
100 µl liquid Concentrated
44497 CD38 1 R (SP149)
1 ml liquid Concentrated
Product Specifications
Designation
IVD
Reactivity
Paraffin
Visualization
Cytoplasmic
Control
Bone marrow, Lymph node, Plasma
cell myeloma, Plasma Cells
Stability
Up to 36 mo. at 2-8°C
Isotype
IgG
Manual Protocol*
• Pretreatment: Heat Induced Epitope
Retrieval (HIER)
• Primary Antibody Incubation Time:
10-30min @ 25-37°C
• 2-step polymer detection
*Please refer to product insert for complete protocol.
ImPath Protocol*
• Dewax: Dewax Solution 2 (DS2)
• Pretreatment: Retrieval Solution pH 9.0
(TR1) 32min @ 98-103°C
• Primary Antibody Incubation Time:
10-90min @ 25-37°C
• HRP Polymer (Universal) or AP Polymer
(Universal) for 12 min
*Please refer to product insert for complete protocol.
Product Description
Anti-CD38 is a very useful immunostaining marker, when combined with antibodies against CD138, MUM1, and EMA in a panel, for the diagnosis
of immunodeficiency-related lymphomas, which usually include plasmablastic lymphoma, primary effusion lymphoma, and large B-cell lymphoma
arising in HHV8-associated multicentric Castleman disease. Such immuno-deficiency-related lymphomas are either pan-B-cell-marker negative
or only weakly positive. Furthermore, IHC detection of plasma cells by anti-CD38 immunohistochemical staining on a bone marrow trephine
biopsy is necessary to obtain the accurate counts of malignant plasma cells needed to make a definitive diagnosis given that malignant plasma
cell counts are difficult to obtain due to sub-optimal bone marrow aspiration, frequent focal distribution of myeloma cells in bone marrow, and
loss of neoplastic plasma cells when manual processing is being performed. Recent studies have demonstrated that anti-CD38, combined with
anti-CD44 (negative) and/or anti-TCL1 (positive), is useful in identifying the cases of large B-cell lymphoma with cMYC gene rearrangement
(respective sensitivity of 82% and 77%; respective specificity of 100% and 100%). Therefore, anti-CD38 is very important in differential diagnosis
of anti-CD20-positive, anti-TdT/anti-cyclin D1-negative diffuse large-to-medium-sized B-cell neoplasms, including diffuse large B-cell lymphoma,
Burkitt lymphoma, and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma.
Lymphoma
CD38 CD138 MUM1 CD20
PAX-5
CD45 CD79a CD30
EMA HHV-8
Plasmablastic Lymphoma
+
+
+
-
-
-
+
+
+
-
Primary Effusion
Lymphoma
+
+
+
-
-
+
-
+
+
+
Large B-cell Lymphoma
arising in HHV8-associated
Multicentric Castleman
Disease
-/+
-
+/-
+
-
+
Extranodal Marginal
Zone Lymphoma with
Plasmacytoid Differentiation
+
+
+
-
-
+
+
Lymphoma
CD38
CD44
TCL1
CD10
BCL2
Large B-cell Lymphoma
with c-Myc Rearrangement
+
-
+
+
-/+
Large B-cell Lymphoma
with no c-Myc
Rearrangement
-
+
-/+
+/-
+
Reference
1. Martin F, Kearney JF. Nat Rev Immunol. 2002; 2:323-335.
67
